AMP 53

Drug Profile

AMP 53

Alternative Names: AZN; Azonafide

Latest Information Update: 07 Jul 2010

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Dec 2003 Development discontinued for Cancer before 2004
  • 20 Oct 1995 Investigation in Cancer in USA (IV)
  • 09 Feb 1995 Preclinical development for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top